Angiogenesis

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Angiogenesis is crucial for tumor growth and expansion.
• Approved angiogenesis inhibitors have broad anticancer activity and minimal side effects.
• Endogenous angiogenesis inhibitors function as tumor suppressor proteins.

Purpose of the Study:

• To review the clinical application of angiogenesis inhibitors in cancer treatment.
• To discuss the principles of angiogenesis research informing drug development.
• To introduce antiangiogenic chemotherapy as a novel approach to overcome drug resistance.

Main Methods:

• Review of clinical trial data and regulatory approvals.
• Analysis of preclinical research on angiogenesis inhibitors.
• Synthesis of information on endogenous angiogenesis inhibitors and host genetic factors.

Main Results:

• Angiogenesis inhibitors are approved globally, including in the US and China.
• Two broad-spectrum angiogenesis inhibitors with minimal side effects have been developed.
• Angiogenic response is influenced by host genetic background.
• Some angiogenesis inhibitors exhibit a U-shaped efficacy curve.

Conclusions:

• Angiogenesis inhibitors represent a significant advancement in cancer therapy.
• Understanding angiogenesis mechanisms is key to developing effective cancer treatments.
• Antiangiogenic chemotherapy offers a new strategy for managing drug-resistant cancers.